Tucatinib vs placebo, both in combination with trastuzumab and capecitabine, for previously treated ERBB2 (HER2)-positive metastatic breast cancer in patients with …

NU Lin, RK Murthy, V Abramson, C Anders… - JAMA …, 2023 - jamanetwork.com
Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …
被引用次数：74 相关文章

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients …

NU Lin, RK Murthy, V Abramson, C Anders, T Bachelot… - 2023 - pubmed.ncbi.nlm.nih.gov
Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …
[HTML] ed.ac.uk

[HTML][HTML] Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in …

NU Lin, RK Murthy, V Abramson, C Anders… - JAMA …, 2022 - research.ed.ac.uk
Importance It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients …

NU Lin, RK Murthy, V Abramson, C Anders… - JAMA …, 2023 - europepmc.org
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for
Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain …
[PDF] core.ac.uk

[PDF][PDF] Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in …

NU Lin, RK Murthy, V Abramson, C Anders, T Bachelot… - JAMA, 2023 - core.ac.uk
OBJECTIVE To describe overall survival (OS) and intracranial outcomes from tucatinib in
combination with trastuzumab and capecitabine in patients with ERBB2-positive MBC and …
[PDF] mbcbrainmets.org

[PDF][PDF] Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in …

NU Lin, RK Murthy, V Abramson, C Anders, T Bachelot… - mbcbrainmets.org
OBJECTIVE To describe overall survival (OS) and intracranial outcomes from tucatinib in
combination with trastuzumab and capecitabine in patients with ERBB2-positive MBC and …
[HTML] nih.gov

[HTML][HTML] Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in …

NU Lin, RK Murthy, V Abramson, C Anders… - JAMA …, 2023 - ncbi.nlm.nih.gov
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously
Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases …

Tucatinib vs Placebo, Both in Combination with Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients …

NU Lin, RK Murthy, V Abramson… - JAMA …, 2023 - mdanderson.elsevierpure.com
Importance: It is estimated that up to 50% of patients with ERBB2 (HER2)-positive metastatic
breast cancer (MBC) will develop brain metastases (BMs), which is associated with poor …

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients …

NU Lin, RK Murthy, V Abramson, C Anders… - JAMA …, 2022 - europepmc.org
Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously
Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases …